New oral anticoagulants and their reversal agents [PDF]
, 2018 Atrial fibrillation is a commonly encountered pathology in medical practice, and its prevalence has shown a continuous rise over the past years. Atrial fibrillation has a significant impact on patients\u27 quality of life, not only due to the standard ...
Bodean, Oana +9 more
core +1 more source
The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. [PDF]
, 2017 The ENSURE-AF study (NCT 02072434) of anticoagulation for electrical cardioversion in nonvalvular atrial fibrillation (NVAF) showed comparable low rates of bleeding and thromboembolism between the edoxaban and the enoxaparin-warfarin treatment arms. This
Al-Saady, N +4 more
core +2 more sources
Epileptic Disorders, EarlyView.Abstract Objectives Antiseizure medications (ASMs) can induce the activity of drug‐metabolizing enzymes and drug transporters, including cytochrome P450 (CYP)2C9 and P‐glycoprotein (P‐gp). Our objective was to comparatively assess the effects of ASMs on exposure to clinical CYP2C9 and P‐gp substrates.
Hagar Cohen +4 more
wiley +1 more source
Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy
Case Reports in Critical Care, 2016 Introduction. The main adverse effect of anticoagulant therapy is bleeding, and major bleeding, including intracranial, gastrointestinal, and retroperitoneal bleeding, has been reported as an adverse effect of edoxaban, a direct oral anticoagulant (DOAC).
Kenichi Nitta +4 more
doaj +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2023 This study aimed to develop a physiologically‐based pharmacokinetic pharmacodynamic (PBPK/PD) parent‐metabolite model of edoxaban, an oral anticoagulant with a narrow therapeutic index, and to predict pharmacokinetic (PK)/PD profiles and potential drug ...
Ruijuan Xu +4 more
doaj +1 more source
Teendők súlyos vérzés vagy sürgős sebészeti beavatkozás esetén direkt orális antikoaguláns gyógyszerrel kezeltekben. Az új dabigatran-antidótum: idarucizumab helye a klinikai gyakorlatban [PDF]
, 2016 Absztrakt Az elmúlt hat évtizedben csak a K-vitamin-antagonista kumarinokat alkalmazhattuk orális antikoagulánsként.
Boda, Zoltán
core +1 more source
Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. [PDF]
, 2017 Nonvalvular atrial fibrillation (AF) is a risk factor for stroke in elderly patients. Although warfarin has been used to prevent AF-associated stroke for more than 50 years, non-vitamin K antagonist oral anticoagulants (NOACs) including dabigatran ...
Alexander +29 more
core +1 more source
New Oral Anticoagulants for Atrial Fibrillation [PDF]
, 2017 Atrial fibrillation (AF) is the most common cardiac arrhythmia in the world. Four new oral anticoagulants have become available as alternatives for warfarin in patients with AF.
Yakobus, Y. (Yuliana)
core +2 more sources
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Diabetic retinopathy (DR) is linked to elevated risks of cerebrovascular diseases. Whether sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduce stroke risk in patients with type 2 diabetes (T2D) and DR remains uncertain. Materials and Methods We conducted a retrospective cohort study using the TriNetX Research Network.
Kuo‐En Chen +3 more
wiley +1 more source
Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital
Journal of Pharmaceutical Health Care and Sciences, 2020 Background The anticoagulant edoxaban is used clinically at doses of 30–60 mg/day; however, we experienced a patient who had taken an overdose of edoxaban of 750 mg.
Koichiro Adachi +5 more
doaj +1 more source